ORAGENICS INC
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED BALANCE SHEETS
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,399,726 | $864,840 |
| Short-term investments | 4,000,000 | - |
| Interest receivable | 53,082 | - |
| Prepaid expenses and other current assets | 1,614,956 | 607,670 |
| Total current assets | 10,067,764 | 1,472,510 |
| Total assets | $10,067,764 | $1,472,510 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,559,011 | $1,355,867 |
| Short-term notes payable, net of debt issuance costs | 227,348 | 328,528 |
| Total liabilities | 1,786,359 | 1,684,395 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, no par value; 50,000,000 shares authorized; 429,291 Series H and 7,488,692 Series F outstanding at December 31, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024. | - | - |
| Common stock, $0.001 par value; 350,000,000 shares authorized; 4,271,529 and 419,003 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively | 4,271 | 419 |
| Additional paid-in capital | 234,905,793 | 216,573,868 |
| Accumulated deficit | (226,628,659) | (216,786,172) |
| Total stockholders’ equity (deficit) | 8,281,405 | (211,885) |
| Total liabilities and stockholders’ equity (deficit) | $10,067,764 | $1,472,510 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.